Dermatology

Systematic Review Does Not Find Significant Risk Associated With a Single Switch

November 12th 2018

By Kelly Davio

Article

As more biosimilars make their way to patients in the United States and Europe, stakeholders seek reassurance on switching to these products. A newly published systematic review sought to investigate the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders.

Patients With Pemphigus Vulgaris May Benefit From Early Rituximab

October 14th 2018

By The Center for Biosimilars Staff

Article

Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.

More Evidence of Low Rates of Adherence and Persistence for Biologics for Inflammatory Diseases

September 13th 2018

By Jackie Syrop

Article

Adherence and persistence rates for biologic drugs are still low in the United States, leading to suboptimal patient outcomes and putting a substantial burden on the healthcare system.

Review Documents 15 Years of Experience With Adalimumab in Psoriasis

August 12th 2018

By The Center for Biosimilars Staff

Article

This Psoriasis Awareness Month, a new review of real-world experience with adalimumab (Humira) in patients with psoriasis finds that adalimumab is slightly less safe, but has better effectiveness and drug survival, than other biologic treatment options.

ICER: IL-23 Inhibitors Are Preferable to Anti-TNF Agents for Plaque Psoriasis

August 7th 2018

By Samantha DiGrande

Article

The Institute for Clinical and Economic Review (ICER) explains that, compared with anti–tumor necrosis factor (anti-TNF) drugs, both guselkumab and risankizumab offered a superior benefit based on currently available data.

Rituximab Granted FDA Approval to Treat Pemphigus Vulgaris

June 8th 2018

By Samantha DiGrande

Article

The FDA has approved Genentech’s innovator rituximab (Rituxan) for the treatment of adults with moderate to severe pemphigus vulgaris (PV). This expanded indication makes the drug the first biologic approved for the treatment of PV, a rare autoimmune disease that affects the skin and mucous membranes with progressive blistering.

Study: Switching to Biosimilar Infliximab Does Not Affect Phosphorylation Levels

January 3rd 2018

By Kelly Davio

Article

A new study used flow cytometry to compare phosphorylation levels of intracellular epitopes in peripheral blood mononuclear cells from patients with psoriasis in clinical remission who were treated with reference infliximab versus healthy controls, and further evaluated whether a switch from reference infliximab to biosimilar CT-P13 affected intracellular phosphorylation patterns.

Infographic: 5 Biologic Treatments for Psoriasis

December 31st 2017

By Samantha DiGrande

Article

There are a variety of biologics available for the treatment of psoriasis; our latest infographic provides examples of each type.

Fresenius Kabi Submits Adalimumab Biosimilar Marketing Application to EMA

December 19th 2017

By Samantha DiGrande

Article

Fresenius Kabi, a subsidiary of the German-based Fresenius SE and Co. KFaA, announced yesterday that its Marketing Authorization Application for MSB11022, an adalimumab (Humira) biosimilar candidate, was submitted and accepted for review by the European Medicines Agency (EMA).

Humira Competitor Tremfya Gains European Approval for Psoriasis Treatment

November 28th 2017

By Jackie Syrop

Article

Janssen-Cilag International’s biologic drug guselkumab (Tremfya) has received approval from the European Commission (EC) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.